Genetic testing for prostate cancer- pro
First, the test appears to not have been performed.
Secondly, VistaSeq prostate panel is a 13 gene profile intended to test presymptomatic patients and assess their risk. In this case, after a prostatectomy, the utility of the test is unproven. There is no information that a panel is superior to individual tests based on family history. Finally, the utility of this test is not prospectively studied, even pre-diagnosis of prostate cancer.
Guideline statements have been reviewed in Genetics of Prostate Cancer (PDQ®)–Health Professional Version, https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq#:~:text=Criteria%20for%20Genetic%20Testing%20in%20Prostate%20Cancer&text=cNCCN%20Prostate%20Cancer%20guidelines,appropriate%20based%20on%20clinical%20context.
Accessed 8/11/2023.
Philadelphia Prostate Cancer Consensus Conference (Giri et al. 2020)
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2023)
NCCN Prostate Cancer (Version 3.2022)c
European Advanced Prostate Cancer Consensus Conference (Gillessen et al. 2017 and Gillessen 2020